Reviva Pharmaceuticals Holdings, Inc. (RVPH)
OTCMKTS · Delayed Price · Currency is USD
0.3521
0.00 (0.00%)
At close: May 14, 2026

RVPH Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
7.98.497.898.085.365.25
Research & Development
9.0311.7122.9131.4222.874.85
Operating Expenses
16.9320.230.839.528.2310.1
Operating Income
-16.93-20.2-30.8-39.5-28.23-10.1
Interest Expense
-0.01-0.01-0.02-0.03--0
Interest & Investment Income
0.310.310.360.40.18-
Other Non Operating Income (Expenses)
0.020.060.56-0.1-0.191.59
Pretax Income
-16.61-19.85-29.9-39.24-28.24-8.52
Income Tax Expense
0.020.020.020.020.020.01
Net Income
-16.63-19.86-29.92-39.26-28.26-8.52
Net Income to Common
-16.63-19.86-29.92-39.26-28.26-8.52
Shares Outstanding (Basic)
542111
Shares Outstanding (Diluted)
542111
Shares Change (YoY)
147.07%114.96%41.84%21.94%31.95%383.10%
EPS (Basic)
-3.49-5.48-17.73-32.99-28.96-11.52
EPS (Diluted)
-3.50-5.48-17.73-32.99-28.96-11.52
EBITDA
------10.1
D&A For EBITDA
-----0
EBIT
-16.93-20.2-30.8-39.5-28.23-10.1
Source: S&P Global Market Intelligence. Standard template. Financial Sources.